AstraZeneca to streamline US commercial business

Wilmington, DE - AstraZeneca (NYSE:AZN) announced today that it will streamline portions of its U.S. commercial business as part of the company's strategy to operate its business more effectively and efficiently to best serve patients in the United States. The changes will enable the company to compete in a challenging environment, including pricing pressures and the continuing growth of generic medicines.

As part of the transformation, AstraZeneca will identify more efficient ways of working throughout its U.S. business and reduce its cost base - including the reduction of approximately 400 positions at the company's Wilmington headquarters and some field-based, non-sales roles.

About 70 of the estimated 400 roles will come from existing vacancies. In addition, employees will have the option to self-identify to potentially leave the company. All decisions will be finalized by early December.

"This will be very difficult for our entire organization, particularly the people who are directly impacted," said Rich Fante, President, AstraZeneca U.S. & CEO, North America. "However, these changes are necessary to build a leaner, more efficient organization that will enable the company to continue delivering against our mission of patient health and sustaining a strong business for years to come."

NOTES TO EDITORS:

About AstraZeneca
AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialization of prescription medicines for gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

For more information about AstraZeneca in the U.S. or our AZ&MeTM Prescription Savings programs, please visit: www.astrazeneca-us.com or call 1-800-AZandMe (292-6363).

Suggested Articles

Creating a relevant online health user experience has its payoffs — for both the user and the brand. Here’s why.

Sanofi's new strategy delivered for the drugmaker in the third quarter as Dupixent posted blockbuster sales and flu vaccines set a revenue record.

Catalent has acquired Bone Therapeutics' cell and gene therapy site in Gosselies, Belgium, to add to its growing "center of excellence" there.